Health Economics›Multiple myeloma›First-line therapy triplets

First-line therapy triplets

Multiple myeloma · 21 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 12 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Dara-Rd Variant #01	—	R 592 167	28d	61.9 mo	—	8	R 1 536 423 PFS proxy	4
KMP Variant #01	—	R 257 211	42d	22.3 mo	—	9	R 1 210 863 PFS proxy	1
KCD Variant #02	—	R 189 620	28d	—	—	~9	~R 908 798 indirect	—
KTD Variant #01	—	R 163 541	28d	—	—	~4	~R 367 757 indirect	—
KRd Variant #08	—	R 147 838	28d	34.6 mo	—	18	R 1 515 571 PFS proxy	2
IRd Variant #03	—	R 65 423	28d	35.3 mo	—	18	R 748 807 PFS proxy	1
VTP Variant #01	—	R 41 024	42d	—	43.0 mo	5	R 109 846 PFS proxy	1
PAD (Pegylated liposomal doxorubicin substituted) Variant #01	—	R 23 109	28d	—	—	~8	~R 184 874 indirect	—
CTD Variant #01	—	R 19 552	21d	—	—	~10	~R 86 855 indirect	—
TAD (Thalidomide) Variant #01	—	R 18 175	28d	—	—	~3	~R 54 524 indirect	—
RVD Variant #07	—	R 17 832	21d	38.7 mo	—	39	R 415 913 PFS proxy	6
VDC Variant #01	—	R 15 305	28d	30.0 mo	—	3	R 45 914 PFS proxy	1
VTD Variant #01	—	R 14 059	21d	35.8 mo	—	4	R 54 155 PFS proxy	1
MPT Variant #01	—	R 12 573	28d	21.2 mo	46.5 mo	12	R 150 877 PFS proxy	7
BBD Variant #01	—	R 12 422	28d	—	—	~8	~R 99 378 indirect	—
PAD Variant #01	—	R 7 335	21d	35.0 mo	—	8	R 58 677 PFS proxy	2
VMP Variant #01	—	R 6 897	42d	17.3 mo	56.4 mo	6	R 41 381 PFS proxy	8
CPR Variant #01	—	R 5 726	28d	20.0 mo	—	10	R 57 260 PFS proxy	2
CRd Variant #03	—	R 3 754	28d	—	—	~12	~R 45 051 indirect	—
Isa-Rd Variant #01 Partial	—	R 2 525	28d	—	—	~19	~R 47 979 indirect	—
MPR Variant #01	—	R 2 245	28d	24.0 mo	—	9	R 20 209 PFS proxy	6

21 of 21 regimens shown